Pharmaceutical - Antibiotics and Infectious diseases

Filter

Popular Filters

101 to 125 of 225 results

Positive top-line Ph III results with ceftolozane/tazobactam in cUTI

25-11-2013

US biopharma company Cubist Pharmaceuticals has revealed positive top-line results from its pivotal Phase…

Antibiotics and Infectious diseasesceftolozaneCubist PharmaceuticalsGenito-urinaryPharmaceuticalResearchtazobactam

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

Eisai takes over marketing authorization for Gliadel, and joins TB partnership

25-11-2013

Japanese drug major Eisai (TYO: 4523) will become the Marketing Authorization Holder for the antineoplastic…

Antibiotics and Infectious diseasesAsia-PacificEisaiGliadelLicensingNobelpharmaOncologyPharmaceutical

TAC puts pressure on Janssen finalize development of TB drug bedaquiline

21-11-2013

The current standard of care for multi-drug resistant tuberculosis (MDR-TB) consists of poorly tested…

Antibiotics and Infectious diseasesbedaquilineJanssenJohnson & JohnsonPharmaceuticalPoliticsResearchRest of the World

AbbVie releases positive Phase III results for oral hepatitis C program

AbbVie releases positive Phase III results for oral hepatitis C program

18-11-2013

US drugmaker AbbVie has released the first Phase III results for the investigational three direct-acting-antiviral…

AbbVieAntibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearchUSA

EU steps up its fight against drug-resistant bacteria

15-11-2013

A survey published by the European Commission today (November 15) reveals a decrease in antibiotic use…

Antibiotics and Infectious diseasesEuropeFinancialPharmaceuticalResearch

UK’s Helperby in deal with Cadila on ARB research and commercialization

14-11-2013

Privately-held Indian drugmaker Cadila Pharmaceuticals and UK based antibiotics discovery company, Helperby…

Antibiotics and Infectious diseasesAsia-PacificCadila PharmaceuticalsHelperby TherapeuticsMarkets & MarketingPharmaceuticalResearch

EMA publishes guidance on anti-bacterials targeted against MDR pathogens

EMA publishes guidance on anti-bacterials targeted against MDR pathogens

07-11-2013

The European Medicines Agency (EMA) has released an addendum to the guideline on the evaluation of medicinal…

Antibiotics and Infectious diseasesEuropeHealthcarePharmaceuticalRegulation

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

A*STAR and AstraZeneca link to combat Gram-negative bacterial infections

05-11-2013

Two units under Singapore’s Agency for Science, Technology and Research (A*STAR) have signed a joint…

A*STARAntibiotics and Infectious diseasesAstraZenecaPharmaceuticalResearch

Roche in-licenses POL7080 from Polyphor in up to 500 million-franc accord

Roche in-licenses POL7080 from Polyphor in up to 500 million-franc accord

04-11-2013

Drug major Roche has entered into an exclusive worldwide license agreement to develop and commercialize…

Antibiotics and Infectious diseasesLicensingPharmaceuticalPOL7080PolyphorRoche

High hopes for Cellceutix’ Brilacidin for serious skin infections

14-10-2013

US clinical-stage biopharmaceutical company Cellceutix says that it is completing the required documentation…

Antibiotics and Infectious diseasesbrilacidinCellceutixDermatologicalsPharmaceuticalResearch

US infectious disease specialists’ prescribing choices for GNIs

US infectious disease specialists’ prescribing choices for GNIs

09-10-2013

A majority of US surveyed infectious disease specialists are willing to prescribe novel antibiotics if…

Antibiotics and Infectious diseasesMarkets & MarketingNorth AmericaPharmaceuticalPricing

Case study draws attention to innovator brand preferences in Kenya

08-10-2013

Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

FDA issues new Boxed Warning on Pfizer antibacterial

FDA issues new Boxed Warning on Pfizer antibacterial

28-09-2013

The US Food and Drug Administration is warning that an additional analysis shows an increased risk of…

Antibiotics and Infectious diseasesNorth AmericaPfizerPharmaceuticalRegulationTygacil

ICAAC: Tetraphase's experimental synthetic tetracycline effective against gonorrhea, intra-abdominal infection and UTIs

16-09-2013

Eravacycline, an experimental agent synthesized from tetracycline, is undergoing Phase III efficacy…

Antibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearchTetracyclineTetraphase Pharmaceuticals

ICAAC: Experimental derivative of spectinomycin could help fill gap for new TB treatment

16-09-2013

An agent referred to as spectinamide 1599, which is a genetically-altered form of a former gonorrhea…

Antibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearch

Antibiotic ceftaroline fosamil shows promise for treating MRSA pneumonia

12-09-2013

A drug approved just two years ago for treating bacterial infections may hold promise for treating the…

Antibiotics and Infectious diseasesAstraZenecaceftaroline fosamilForest LaboratoriesPharmaceuticalResearchTeflaroZinforo

Actelion to start Phase III studies into cadazolid for C. difficile related diarrhea

11-09-2013

Swiss biotech firm Actelion (SIX: ATLN) will initiate a Phase III clinical development program to assess…

ActelionAntibiotics and Infectious diseasescadazolidEuropePharmaceuticalResearchVancomycin

Antimicrobial Resistance Strategy launched in UK

11-09-2013

The UK's Department of Health has launched a five year Antimicrobial Resistance Strategy. The scale of…

Antibiotics and Infectious diseasesEuropeHealthcarePharmaceutical

Bayer in settlement over Cipro pricing

04-09-2013

A partial settlement has been reached in a US class action law suit involving the prescription antibiotic…

Antibiotics and Infectious diseasesBayerCiproGenericsLegalNorth AmericaPharmaceuticalPricing

Rise in infections means hepatitis C market is expected to peak at $15.5 billion in 2022

27-08-2013

The hepatitis C market is forecast to increase by a massive 230% in the next nine years, according to…

AbbVieAntibiotics and Infectious diseasesBristol-Myers SquibbGilead SciencesGlobalJohnson & JohnsonMarkets & MarketingPharmaceuticalsofosbuvir

Merck KGaA launches donation program for praziquantel in Sudan

27-08-2013

German health care and chemicals firm Merck KGaA (MRK: DE) has donated six million praziquantel tablets…

Antibiotics and Infectious diseasesHealthcareMerck KGaAPharmaceuticalpraziquantelRest of the World

Theravance reintroduces Vibativ in USA

14-08-2013

US drug developer Theravance (Nasdaq: THRX) says it has commenced shipments of Vibativ (telavancin) into…

Antibiotics and Infectious diseasesAstellas PharmaMarkets & MarketingNorth AmericaPharmaceuticalProductionTheravanceVibativ

Cubist Pharma signs two acquisition deals in one day

31-07-2013

In what must have been a busy day for US drugmaker Cubist Pharmaceuticals (Nasdaq: CBST) announced not…

Antibiotics and Infectious diseasesCubist PharmaceuticalsDificidMergers & AcquisitionsOptimer PharmaceuticalsPharmaceuticaltedizolidTrius Therapeutics

101 to 125 of 225 results

Back to top